You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Are There Disparities in Hepatitis B Treatment?

  • Authors: News Author: Marcia Frellick; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 5/5/2023
  • Valid for credit through: 5/5/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, infectious disease clinicians, family medicine/primary care clinicians, internists, public health and prevention officials, nurses, pharmacists, physician assistants, and other members of the health care team for patients with chronic hepatitis B infection.

The goal of this activity is for the healthcare team to be better able to compare hepatitis B virus treatment initiation and outcomes among racial groups, based on the multicenter longitudinal Hepatitis B Research Network cohort study conducted in North America.

Upon completion of this activity, participants will:

  • Assess hepatitis B virus treatment initiation and outcomes, compared among racial groups, based on the Hepatitis B Research Network longitudinal cohort study
  • Evaluate the clinical and public health implications of hepatitis B virus treatment initiation and outcomes, compared among racial groups, based on the Hepatitis B Research Network longitudinal cohort study
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Marcia Frellick

    Freelance writer, Medscape

    Disclosures

    Marcia Frellick has no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has no relevant financial relationships.

Editor/Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-159-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 05/05/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Are There Disparities in Hepatitis B Treatment?

Authors: News Author: Marcia Frellick; CME Author: Laurie Barclay, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/5/2023

Valid for credit through: 5/5/2024, 11:59 PM EST

processing....

Clinical Context

Estimated US prevalence of chronic hepatitis B (CHB) is 2.4 million. CHB disproportionately affects persons of Asian or African descent. Compared with White people with CHB, Asian American and African American or Black people also have higher hepatocellular carcinoma (HCC) incidence and develop HCC at an earlier age.

Earlier Hepatitis B Research Network analyses found significant differences in presumed mode of infection, hepatitis B virus (HBV) genotype, hepatitis B e antigen status, HBV DNA levels, and alanine aminotransferase (ALT) levels across racial groups and among African American and Black people, including significant differences between those born in the US, East Africa, and West Africa.

Study Synopsis and Perspective

Researchers studying differences in treatment initiation for CHB among a large, multiracial cohort in North America did not find evidence of disparities by race or socioeconomic status.

Instead, they observed a similar gap across races between the number of people eligible for treatment and those receiving it.

That gap suggests that treatment guidelines need to be simplified and that efforts to increase HBV awareness and train more clinicians are needed to achieve the World Health Organization’s goal of eliminating HBV by 2030, the researchers write.

The Hepatitis B Research Network study was published online April 10 in JAMA Network Open.[1]

The prevalence of CHB in the United States is estimated at 2.4 million. It disproportionately affects persons of Asian or African descent, the investigators note. Their study examined whether treatment initiation and outcomes differ between African American or Black, Asian, and White participants, as well as between African American and Black participants born in North America and East or West Africa.

The research involved 1550 adult patients: 1157 Asian American, 193 African American or Black (39 born in the United States, 90 in East Africa, 53 in West Africa, and 11 elsewhere), 157 White, and 43 who identified as being of “other races.” All had CHB but were not receiving antiviral treatment at enrollment.

Participants came from 20 centers in the United States and 1 in Canada. They underwent clinical and laboratory assessments and could receive anti-HBV treatment after they enrolled. Enrollment was from January 14, 2011, to January 28, 2018. Participants were followed at 12 and 24 weeks, and every 24 weeks thereafter, in the longitudinal cohort study by Mandana Khalili, MD, Division of Gastroenterology and Hepatology, University of California, San Francisco, and colleagues.

Information on patients’ country of birth, duration of US or Canadian residency, educational level, employment, insurance, prior antiviral treatment, family history of HBV or HCC, and mode of transmission were collected by research coordinators.

Treatment Initiation

During the study period, slightly fewer than one third (32.5%) of the participants initiated treatment. The incidences were 4.8 per 100 person-years in African American or Black participants, 9.9 per 100 person-years in Asian participants, 6.6 per 100 person-years in White participants, and 7.9 per 100 person-years in those of other races (P<.001).

A lower percentage of African American and Black participants (14%) met the American Association for the Study of Liver Diseases treatment criteria compared with Asian (22%) and White (27%) participants (P=.01).

When the researchers compared cumulative probability of initiating treatment by race for those who met criteria for treatment, they found no significant differences by race.

At 72 weeks, initiation probability was 0.45 for African American and Black patients and 0.51 for Asian and White patients (P=.68). Similarly, among African American and Black participants who met treatment criteria, there were no significant differences in cumulative probability of treatment by region of birth.

The cumulative percentage of treatment initiation for those who met guideline-based criteria was 62%.

“Among participants with a treatment indication, treatment rates did not differ significantly by race, despite marked differences in educational level, income, and type of health care insurance across the racial groups,” the researchers write. “Moreover, race was not an independent estimator of treatment initiation when adjusting for known factors associated with a higher risk of adverse clinical outcomes, namely, HBV DNA, disease severity, sex, and age.”

Adverse liver outcomes (hepatic decompensation, HCC, liver transplant, and death) were rare and did not vary significantly by race, the researchers write.

One study limitation is that participants were linked to specialty liver clinics, so the findings may not be generalizable to patients who receive care in other settings, the authors note.

The results are “reassuring,” said senior author Anna S. Lok, MD, Division of Gastroenterology and Hepatology at University of Michigan in Ann Arbor. However, she noted, study participants had already overcome barriers to receiving care at major academic centers.

Many factors drive the decision to undergo treatment, including the physician’s opinion as to need and the patient’s desire to receive treatment, she said.

The study participants who were more likely to get treated were those with higher-level disease who had a stronger indication for treatment, Dr Lok said.

Finding the Disparities

Centers for Disease Control and Prevention statistics show that Black people are 3.9 times more likely to have CHB and 2.5 times more likely to die from it than White people, notes H. Nina Kim, MD, from the Department of Medicine, University of Washington, Seattle, in an accompanying invited commentary.[2]

“The fact that we have not observed racial disparities in treatment initiation does not mean none exist; it means we have to look harder to find them,” she writes.

“We need to examine whether our guidelines for HBV treatment are so complex that it becomes the purview of specialists, thereby restricting access and deepening inequities,” Dr Kim adds. “We should look closely at retention in care, the step that precedes treatment, and stratify this outcome by race and ethnicity.”

Primary care clinicians in some regions might find it difficult to manage patients who have hepatitis B because they see so few of them, Dr Lok noted.

Dr Khalili has received grants and consulting fees from Gilead Sciences Inc and grants from Intercept Pharmaceuticals outside the submitted work. Dr Lok has received grants from Target and consultant fees from Abbott, Ambys, Arbutus, Chroma, Clear B, Enanta, Enochian, GNI, GlaxoSmithKline, Eli Lilly, and Virion outside the submitted work. Coauthors have received grants, consulting fees, or personal fees from Bayer, Boston Scientific, Exact Sciences, Fujifilm Medical Sciences, Gilead Sciences Inc, Glycotest Inc, Redhill Biopharma, Target RWE, MedEd Design LLC, Pontifax, Global Life, the Lynx Group, AstraZeneca, Eisai, Novartis Venture Fund, Grail Inc, QED Therapeutics, Genentech, Hepion Pharmaceuticals, Roche, Abbott, AbbVie, and Pfizer. Editorialist Dr Kim has received grants from Gilead Sciences (paid to her institution) outside the submitted work.

JAMA Network Open. Published online April 10, 2023.

Study Highlights

  • From January 14, 2011, to January 28, 2018, hepatitis B e antigen-positive adults (aged ≥18) not receiving anti-HBV therapy were enrolled in Hepatitis B Research Network and followed up at weeks 12 and 24, and every 24 weeks thereafter (last study visit, January 28, 2019).
  • Exclusion criteria were acute HBV, HIV, hepatitis C or D, fewer than 24-weeks’ follow-up after enrollment, treatment initiation at or immediately after enrollment, or unknown race.
  • Participants (n=1550; 51% women; median age 41.2 [IQR, 32.9-51.6] years) had clinical and laboratory assessments and could receive anti-HBV treatment after enrollment.
  • Racial composition was 12% African American or Black, 75% Asian, 10% White, and 3% other.
  • Groups differed in sociodemographic and virologic parameters.
  • During 5727 person-years of follow-up, 504 participants began treatment, with incidences per 100 person-years of 4.8 in African American or Black people, 9.9 in Asian people, 6.6 in White people, and 7.9 in those of other races (P<.001).
  • Treatment criteria were met by 14% of African American or Black people vs 22% of Asian people and 27% of White people (P=.01).
  • Overall, 62% of treatment-eligible participants began treatment by 144 weeks after meeting criteria; most began by 48 weeks.
  • Higher ALT levels, HBV DNA levels, and cirrhosis were associated with significantly shorter time to treatment initiation.
  • Cumulative probabilities of treatment initiation by 144 weeks after meeting criteria (0.64 per 100 person-years overall) did not differ significantly among racial groups (African American or Black, 0.45; Asian, 0.38; White, 0.40 at 48 weeks, and 0.45, 0.51, and 0.51, respectively, at 72 weeks; P=.68).
  • Differences in educational level, household income, types of health care insurance, and duration of North American residence had no association with treatment initiation among those meeting criteria.
  • Incidence of major adverse liver outcomes (hepatic decompensation, HCC, liver transplant, and death) was 0.1/100 person-years and did not differ by race.
  • The investigators concluded that racial disparity was not identified in rates of treatment initiation among patients with CHB meeting treatment criteria.
  • African American or Black participants were less likely than individuals of other races to meet treatment criteria, but among those who did, HBV treatment receipt did not differ significantly by race or socioeconomic factors, after adjusting for known factors associated with a higher risk for adverse clinical outcomes (HBV DNA, disease severity, sex, and age).
  • Not all eligible participants started treatment, but adverse liver outcomes were rare.
  • As this observational study took place at specialized liver treatment centers, the findings may not be generalizable to patients with chronic HBV in other settings.
  • All participants were linked to liver specialists who may have increased treatment rates or had access to Hepatitis B Research Network treatment trials, contributing to the lack of differences in treatment initiation rates by race among those meeting treatment criteria.
  • Limited data may have underestimated the effect of socioeconomic factors.
  • The treatment gap between participants eligible for and those receiving treatment suggests that increasing HBV awareness and training of clinicians, and simplifying treatment guidelines, are needed to achieve World Health Organization goals of HBV elimination by 2030.
  • Future research should examine retention in care, stratified by race and ethnicity.

Clinical Implications

  • Racial disparity was not identified in rates of treatment initiation among patients with CHB meeting treatment criteria.
  • Failure to observe racial disparities in treatment initiation does not prove their absence.
  • Implications for the Health Care Team: Increased HBV awareness and training of clinicians, and simplifying treatment guidelines, are needed to achieve World Health Organization goals of HBV elimination by 2030.

 

Earn Credit

  • Print